Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)

Journal of Clinical Apheresis
Massimo MartinoPasquale Lacopino

Abstract

No specific characteristics have been identified as predictors of peripheral blood stem cells (PBSC) mobilization in healthy donors. In this study, clinical characteristics and laboratory data for 122 healthy donors who underwent apheresis on day 5 of treatment with recombinant granulocyte colony-stimulating factor (G-CSF) were retrospectively analyzed for correlations with CD34(+) cell mobilization. The variables that were analyzed included age, sex, body weight, basal complete blood count, and maximum white blood count (WBC) before apheresis, G-CSF type, and dosage. Median age and body weight were 42.5 years (range 16-65) and 72.5 kg (range 47-121), respectively. By univariate analysis, male sex (P = 0.007), body weight (< or = 70 vs. >70 kg, P = 0.04), and donor's age (< or = 50 vs. > 50 years; P = 0.015) were correlated with the number of CD34(+) cells mobilized. By multivariate analysis, donor's age and male sex were the only two variables that significantly predicted a high CD34(+) cell level. In conclusion, our data suggest that male sex and younger age are the only factors that significantly affect CD34(+) mobilization in healthy donors.

References

May 1, 1997·British Journal of Haematology·P AnderliniM Körbling
Jun 1, 1997·Journal of Hematotherapy·A TabilioM F Martelli
Feb 26, 1999·Bone Marrow Transplantation·R BellucciP de Fabritiis
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M EngelhardtJ Finke
Mar 10, 2001·Transfusion·J de La RubiaM A Sanz
Mar 16, 2002·Transfusion·Javier de la RubiaUNKNOWN Spanish Group of Allogeneic Peripheral Blood Stem Cell Transplantation

❮ Previous
Next ❯

Citations

Aug 13, 2011·Internal Medicine Journal·K E HerbertL B To
Feb 12, 2011·Journal of Clinical Apheresis·Daniel LysákPavel Jindra
Sep 17, 2011·Pathology·L Bik ToIan D Lewis
Jul 31, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Juliane LenkChristian Thiede
Jun 12, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aazim K OmerKaren K Ballen
May 4, 2021·Arthroscopy : the Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association·Adam W AnzKhay-Yong Saw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.